Single Cell Technology and Open Monoclonal Technology Announce Human Antibody Discovery and Development Collaboration

SAN JOSE, Calif. & PALO ALTO, Calif.--(BUSINESS WIRE)--Single Cell Technology, Inc. (SCT) and Open Monoclonal Technology, Inc. (OMT) today announced a new collaboration where OMT will use its OmniRat™ transgenic animal platform to generate human antibodies against a therapeutic target identified by SCT. SCT will utilize its patented platform to massively screen plasma cells, measure the kinetics of secreted antibodies, and sequence the cognate light and heavy chain mRNA powered by Next Generation Sequencing (NGS). SCT will advance and partner the program and share the economics with OMT depending on the stage of development. SCT will also have an option to develop and commercialize selected products resulting from the research.